Humans have been fighting cancer since it was discovered. Although cancer is still not curable, with the improvement of medical standards, more and more anti-cancer drugs have been developed, bringing hope to the majority of cancer patients.

Humans have been fighting cancer since it was discovered. Although cancer is still not curable, with the improvement of medical standards, more and more anti-cancer drugs have been developed, bringing hope to the majority of cancer patients.

Not long ago, at the 2020 World Lung Cancer Conference, my country's innovative drug anlotinib , developed independently, was grandly unveiled with 23 new treatment studies, which means that my country has made another major breakthrough in its anti-cancer cause.

So, what is this highly anticipated domestic targeted drug anlotinib? How many patients can benefit from it? Let's take a look together.

After ten years, it has finally become a variety of cancer patients. The gospel

Anlotinib is an vascular inhibitor , which can effectively inhibit vascular endothelial growth factor receptor, platelet-derived growth factor receptor, etc. prevents tumor angiogenesis and eliminates tumors in the budding state. In simple terms, can "starve" cancer cells.

From the time of applying for the compound patent in 2007 to the time of applying for the market in 2017, anlotinib finally "was ready to see the bright moon."

In October 2017, anlotinib became the new third-line treatment standard for advanced non-small cell lung cancer . Clinical trials have shown that anlotinib can extend progression-free survival to 5.37 months and overall survival of 9.6 months in patients with advanced non-small cell lung cancer, and is generally safe. Judging from the long-term follow-up cases, no unpredictable toxic side effects were found in anlotinib.

As the research deepens, the scope of application of anlotinib has been further expanded. According to the results of the current clinical trials, in addition to being effective against non-small cell lung cancer, anlotinib has good therapeutic effects on colorectal cancer, thyroid cancer, liver cancer, breast cancer, kidney cancer and other cancers.

3 indications are included in medical insurance, and the fourth indication is newly approved

At the end of last year, anlotinib was listed in the new version of the national medical insurance catalog released by the National Health Insurance Administration. In addition to non- small cell lung cancer , indications for small cell lung cancer and soft tissue sarcoma have also been officially included in the catalog. The three major indications of anlotinib were included in the national medical insurance catalog, further expanding the beneficiary population.

• Non-small cell lung cancer (NSCLC) : Patients with locally advanced or metastatic NSCLC who have experienced disease progression or recurrence after receiving at least 2 systemic chemotherapy.
• Small cell lung cancer (SCLC) : Patients with SCLC who have experienced at least 2 chemotherapy regimens before progressing or recurring.
• Soft Tissue Sarcoma (STS): Aceroid soft tissue sarcoma, clear cell sarcoma, and other patients with advanced STS who have been treated at least with anthracycline-containing chemotherapy regimens.

In addition, the fourth indication of anlotinib has recently received good news: the fourth indication of anlotinib, , advanced or metastatic medullary thyroid carcinoma (MTC), , was officially approved in China.

study results show that anlotinib is effective in the treatment of locally advanced or metastatic medullary thyroid carcinoma, extending the patient's median progression-free survival by 9.6 months, the objective response rate reached 48.39% , and the disease control rate reached 88.71% , and the safety and tolerability were good.

Take anlotinib, 5 common adverse reactions

Although anlotinib has many advantages, like many other anti-cancer drugs, side effects will inevitably occur. According to research, the five common adverse reactions of anlotinib are:

• 1. Hypertension

Anlotinib is a VEGFR vascular inhibitor targeted drug. It aims to improve the tumor microenvironment by inhibiting angiogenesis around tumor cells.

Among them, elevated blood pressure is the most common adverse reaction of anlotinib, which usually occurs about 2 weeks after taking the medication. Patients can take routine antihypertensive drugs to control blood pressure under the guidance of a doctor.

• 2. Hand and foot skin reaction

is mainly manifested as The palms and soles of the feet turn red, accompanied by swelling and tingling . According to different degrees, it can be divided into level 1, level 2 and level 3. In severe cases, skin peeling, bleeding, etc. will occur, affecting normal life.

treatment method is to keep the skin clean by , minimize the pressure and friction on the skin, and use moisturizers, and use antifungal or antibiotics when necessary.

• 3.Proteinuria

Proteinuria refers to an increase in the protein content in the urine, which is specifically manifested as a large amount of foam in the urine and does not dissipate for a long time.

Similarly, according to the adverse reaction level, proteinuria can be divided into grade 1, 2, 3 and 4. The response measures include dose adjustment, drug discontinuation, etc.

• 4. Hypothyroid

Anlotinib can cause thyroid deterioration, thereby causing symptoms of general fatigue.

Therefore, it is recommended to check thyroid function regularly during anlotinib. If hypothyroidism occurs, you can take Yujiale in moderation to improve your physical fitness.

5. Bleeding

Hemorrhage is divided into two types: one is mucosal bleeding, and the other is tumor bleeding. Common bleeding sites include gums, mouth, digestive tract, bronchus, etc.

The method of dealing with bleeding is also analysed according to the severity of the symptoms and specific circumstances, such as suspension of medication, permanent termination of treatment, etc.

In addition, the adverse reactions of anlotinib include liver function abnormalities, oral ulcers, and loss of appetite . However, these adverse reactions are not worth mentioning compared to the effects of anlotinib. As long as you actively respond to adverse reactions, the benefits of anlotinib can be maximized.

Anlotinib is the light of Sinopharm. With the deepening of research, I believe that in the near future, more and more anlotinib indications will be included in medical insurance, benefiting the majority of cancer patients. Therefore, on the road to tumor treatment, we must not sit still and wait for death. With the support of Sinopharm, which is constantly developed and marketed, cancer patients can greatly prolong their survival. #Qingfeng Plan# #Yao Zero Plan# #Follow her health#

References:

[1] "Add to the light of the original research together! 23 studies of anlotinib topped the 2020 WCLC! 》. China Medical Tribune Today's Tumor. 2021-01-30

[2] "Analysis of Domestic Cancer Magical Drug Anlotinib and Treatment of Side Effects". NetEase News. 2019-02-26

[3] "The fourth indication of the anti-cancer drug Anlotinib for the treatment of medullary thyroid cancer, Zhengda Tianqing's anti-cancer drug Anlotinib is approved." Health Times. 2021-02-02

Reproduction of